Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
Digestive Diseases and Sciences · 2024-10 · 69 (10) · 3920-3931
DOI: 10.1007/s10620-024-08515-5 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 14.06.2024. Verfasst von Jeffrey A Lowell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Manhasset, NY, 11030, USA. jlowell@northwell.edu. Hauptthemen laut MEDLINE: Immunomodulating Agents, Inflammatory Bowel Diseases, Infliximab. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) receiving infliximab (IFX) commonly experience immunogenic loss of response (LOR) by formation of anti-drug antibodies (ADAs). An immunomodulator (IMM) used in combination with initial IFX induction is known to reduce ADA development and improve clinical outcomes. We aimed to assess the impact of reactively adding an IMM to patients on IFX monotherapy. METHODS: We conducted a retrospective cohort study and systematic review with meta-analysis of patients with IBD demonstrating immunologic LOR, with or without clinical LOR, that had an IMM (azathioprine, 6-mercaptopurine, or methotrexate) reactively added (reactive combination therapy; rCT) to combat elevated ADAs and raise IFX level. Data were extracted for pooled effect size estimation using random-effects models, and ADA and IFX trough levels were compared pre- and post-IMM initiation. RESULTS: We identified 6 patients who received rCT due to rising ADA titers and low IFX levels. Median ADA titer decreased from 506 ng/mL (interquartile range (IQR) [416-750]) to 76.5 ng/mL (IQR [25.8-232]), an 85% decrease (p = 0.031). Median IFX trough increased from 0.4 µg/mL (IQR [0.4-0.48]) to 8.25 µg/mL (IQR [3.7-9.6]), a 20.6-fold increase (p = 0.038). Meta-analysis pooled effect size of 7 studies with 89 patients showed an 87% ADA titer reduction [95% confidence interval (CI) = 72-94%], 6.7-fold increased IFX trough (95% CI = 2.4-18.7), and 76% clinical remission rescue rate (95% CI = 59-93%). CONCLUSIONS: These results suggest rCT is a valid rescue strategy in patients with immunogenic LOR to IFX to reduce ADA titers, restore therapeutic IFX levels, and recapture clinical remission of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Manhasset, NY, 11030, USA. jlowell@northwell.edu.
- , 300 Community Drive, Manhasset, NY, 11030, USA. jlowell@northwell.edu.
- Arkansas College of Osteopathic Medicine, Fort Smith, AR, 72916, USA.
- Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 11030, USA.
- Gastroenterology Department, Sheba Medical Center, Tel-Aviv University, Tel Aviv, Israel.
- Division of Gastroenterology, Lenox Hill Hospital, Northwell Health, New York, NY, 10075, USA.
Zitieren
APA
Lowell, J. A., Sharma, G., Chua, V., Ben-Horin, S., Swaminath, A., & Sultan, K. (2024). Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis. Digestive Diseases and Sciences, 69(10), 3920-3931. https://doi.org/10.1007/s10620-024-08515-5
Vancouver
Lowell JA, Sharma G, Chua V, Ben-Horin S, Swaminath A, Sultan K. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis. Digestive Diseases and Sciences. 2024;69(10):3920-3931. doi:10.1007/s10620-024-08515-5
BibTeX
@article{Lowell2024,
author = {Lowell, Jeffrey A and Sharma, Garvita and Chua, Vincent and Ben-Horin, Shomron and Swaminath, Arun and Sultan, Keith},
title = {Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis},
journal = {Digestive Diseases and Sciences},
year = {2024},
volume = {69},
number = {10},
pages = {3920--3931},
doi = {10.1007/s10620-024-08515-5}
}
EUVIMED